Total Payments
$611,455
2024 Payments
$70,264
Companies
82
Transactions
1,709
Medicare Patients
3,583
Medicare Billing
$951,699
Payment Breakdown by Category
Other$428,281 (70.0%)
Consulting$93,382 (15.3%)
Travel$56,956 (9.3%)
Food & Beverage$31,547 (5.2%)
Education$1,263 (0.2%)
Gifts$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $412,691 | 227 | 67.5% |
| Consulting Fee | $93,382 | 53 | 15.3% |
| Travel and Lodging | $56,956 | 111 | 9.3% |
| Food and Beverage | $31,547 | 1,277 | 5.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,150 | 7 | 2.2% |
| Honoraria | $1,875 | 3 | 0.3% |
| Education | $1,263 | 29 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.1% |
| Gift | $25.00 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $194,089 | 276 | $0 (2024) |
| Celgene Corporation | $78,425 | 120 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $65,559 | 97 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $58,967 | 106 | $0 (2024) |
| Eisai Inc. | $51,656 | 85 | $0 (2024) |
| GENZYME CORPORATION | $31,455 | 47 | $0 (2023) |
| INSYS Therapeutics Inc | $27,728 | 19 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $24,902 | 23 | $0 (2024) |
| Helsinn Therapeutics (U.S.), Inc. | $10,742 | 16 | $0 (2019) |
| Astellas Pharma US Inc | $8,067 | 34 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,264 | 180 | E.R. Squibb & Sons, L.L.C. ($17,841) |
| 2023 | $115,858 | 264 | Eisai Inc. ($26,812) |
| 2022 | $90,480 | 262 | E.R. Squibb & Sons, L.L.C. ($27,548) |
| 2021 | $59,880 | 199 | Amgen Inc. ($24,379) |
| 2020 | $35,079 | 126 | AstraZeneca Pharmaceuticals LP ($11,235) |
| 2019 | $87,146 | 235 | Amgen Inc. ($43,789) |
| 2018 | $56,854 | 183 | Amgen Inc. ($41,202) |
| 2017 | $95,893 | 260 | Amgen Inc. ($37,570) |
All Payment Transactions
1,709 individual payment records from CMS Open Payments — Page 1 of 69
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/16/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological), Udenyca | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.67 | General |
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $25.57 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $779.64 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $115.56 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $22.41 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $27.59 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $107.19 | General |
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Biological) | Education | In-kind items and services | $83.99 | General |
| Category: Rare Disease | ||||||
| 12/04/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/02/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: BioOncology | ||||||
| 12/01/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $6.86 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Oncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $86.53 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,684.00 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $8.06 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 839 | 1,594 | $593,817 | $195,766 |
| 2022 | 13 | 797 | 1,638 | $610,564 | $209,633 |
| 2021 | 12 | 852 | 1,764 | $759,567 | $248,110 |
| 2020 | 11 | 1,095 | 2,282 | $981,130 | $298,190 |
Total Patients
3,583
Total Services
7,278
Medicare Billing
$951,699
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 75 | 115 | $418,600 | $116,179 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 300 | 800 | $68,494 | $46,050 | 67.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 75 | 115 | $64,688 | $11,270 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 75 | $8,647 | $6,381 | 73.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $5,672 | $3,676 | 64.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 28 | $8,243 | $3,531 | 42.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 73 | 86 | $5,136 | $3,041 | 59.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 25 | $4,202 | $1,491 | 35.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 105 | 165 | $3,218 | $1,357 | 42.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 21 | 21 | $1,718 | $1,244 | 72.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 32 | $1,036 | $701.75 | 67.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 37 | 68 | $3,128 | $495.60 | 15.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 18 | 23 | $1,035 | $348.81 | 33.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 74 | 118 | $429,520 | $122,324 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 326 | 926 | $72,395 | $50,311 | 69.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 75 | 118 | $66,375 | $12,110 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 54 | 101 | $11,023 | $8,477 | 76.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 33 | $11,680 | $4,923 | 42.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 41 | 41 | $5,213 | $3,746 | 71.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 35 | $4,202 | $1,884 | 44.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $2,147 | $1,695 | 79.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 41 | $2,097 | $1,453 | 69.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 41 | 64 | $1,673 | $1,199 | 71.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 11 | 11 | $847.00 | $577.45 | 68.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $935.40 | $562.93 | 60.2% |
About Dr. Nicola Jabbour, M.D
Dr. Nicola Jabbour, M.D is a Hematology & Oncology healthcare provider based in Lexington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740485168.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicola Jabbour, M.D has received a total of $611,455 in payments from pharmaceutical and medical device companies, with $70,264 received in 2024. These payments were reported across 1,709 transactions from 82 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($412,691).
As a Medicare-enrolled provider, Jabbour has provided services to 3,583 Medicare beneficiaries, totaling 7,278 services with total Medicare billing of $951,699. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Lexington, KY
- Active Since 06/16/2007
- Last Updated 01/11/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1740485168
Products in Payments
- REBLOZYL (Biological) $75,288
- XGEVA (Biological) $52,771
- Lenvima (Drug) $51,452
- LUMAKRAS (Drug) $28,021
- LIBTAYO (Biological) $27,780
- SUBSYS (Drug) $27,714
- Kyprolis (Biological) $24,334
- TAGRISSO (Drug) $23,850
- Neulasta (Biological) $23,143
- ELITEK (Drug) $22,633
- IMFINZI (Biological) $21,166
- Prolia (Biological) $18,427
- Abraxane (Drug) $16,789
- Vectibix (Biological) $16,447
- Pomalyst (Drug) $16,045
- Kyprolis (Drug) $13,932
- Revlimid (Drug) $11,882
- AKYNZEO (Drug) $10,689
- PADCEV (Biological) $10,529
- ZEJULA (Drug) $7,855
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lexington
Dr. Lowell Anthony, M.d, M.D
Hematology & Oncology — Payments: $64,060
Hematology & Oncology $64,060
Dr. Zhonglin Hao, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $22,675
Hematology & Oncology $22,675
John Villano
Hematology & Oncology — Payments: $17,051
Hematology & Oncology $17,051
Dr. Jessica Croley, Md, MD
Hematology & Oncology — Payments: $13,189
Hematology & Oncology $13,189
Mr. Russell Eldridge, Md, MD
Hematology & Oncology — Payments: $10,781
Hematology & Oncology $10,781
Reinhold Munker
Hematology & Oncology — Payments: $9,229
Hematology & Oncology $9,229